Control of warfarin treatment in patients with antiphospholipid syndrome and falsely high INR at point-of-care-testing
Open Access
- 28 May 2025
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 252, 109361
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Interference of lupus anticoagulant causing antiprothrombin and anti–beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized ratio methodsResearch and Practice in Thrombosis and Haemostasis, 2024
- The 2023 ACR/EULAR Antiphospholipid Syndrome Classification CriteriaArthritis & Rheumatology, 2023
- Interference in point-of-care international normalized ratio monitoring in patients with lupus anticoagulant is correlated with anti–β2-glycoprotein I antibody titersResearch and Practice in Thrombosis and Haemostasis, 2023
- Warfarin Is the Preferred Therapy for Patients With Thrombotic APSJACC, 2022
- Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid SyndromesJACC, 2022
- Warfarin monitoring and interference by lupus anticoagulant in patients with antiphospholipid syndromeThrombosis Research, 2022
- Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndromeAnnals of Hematology, 2015
- Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-AntagonistsThrombosis Research, 2012
- Results of the performance verification of the CoaguChek XS systemThrombosis Research, 2008
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999